Tara A Nazareth1, Andrew R Rava2, Jackie L Polyakov3, Edward N Banfe4, Royce W Waltrip Ii5, Kristine B Zerkowski6, Leslie B Herbert7. 1. Autoimmune and Rare Diseases, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. Electronic address: tara.nazareth@mnk.com. 2. Autoimmune and Rare Diseases, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. Electronic address: andrewrava23@gmail.com. 3. Autoimmune and Rare Diseases, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. Electronic address: Jackie.Polyakov@mnk.com. 4. Autoimmune and Rare Diseases, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. Electronic address: Edward.Banfe@mnk.com. 5. Autoimmune and Rare Diseases, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA. Electronic address: Royce.Waltrip@mnk.com. 6. Community Development, Health Union, Philadelphia, PA, USA. Electronic address: kristine.zerkowski@health-union.com. 7. Research and Analytics, Health Union, Philadelphia, PA, USA. Electronic address: lb.herbert@health-union.com.
Abstract
BACKGROUND: Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). OBJECTIVE: To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Sclerosis in America (MSIA) 2017 survey. METHODS: Information on patient demographics, health insurance coverage, symptoms, disability, relapses, and related HCP interactions were captured. Descriptive analyses were conducted and relapses were annualized. Chi-square tests were used to evaluate frequency of patient engagement, i.e. speaking with or seeing their HCP during relapse with annualized relapse frequency and topics discussed. RESULTS: Of the 5,311 patient-respondents, the mean age was 51.2 years (84.3% female, 89.3% Caucasian); 40.1% were on disability, and 96.8% had health insurance coverage. A total of 72.2% of patients were diagnosed with relapsing-remitting MS (RRMS); 74.8% of patients not reporting a diagnosis of primary progressive MS (PPMS) (n = 4819) were using disease-modifying therapy. In the 2 years preceding the survey, 73.1% experienced a relapse for a median number of 2 relapses; this corresponded to an annualized relapse distribution among all patients of 44.1% with < 1 relapse, 35.5% with 1-2 relapses, and 20.2% with > 2 relapses. In patients reporting relapses, 62.5% cited an average relapse duration of < 1 month, 10.9% cited 1-2 months, and 13.6% cited > 2 months (12.9% were unsure/didn't recall). Leading symptoms experienced with MS relapse were fatigue (77.4%), numbness/tingling (70.0%), and walking or balance issues (68.8%). With respect to HCP engagement during relapse, 46.9% of patients reported doing so always/often, vs. sometimes (27.3%), rarely (18.5%), and never (7.3%). The most common reasons cited for not engaging an HCP were that the relapse was not severe enough (57.9%), the HCP was unhelpful or didn't specifically tell the patient to contact them (30.9%), the treatment didn't work well or wasn't tolerated (25.6%), or the preference to manage alone (24.4%). A higher percentage of patients with 1 relapse coincided with the highest frequency of HCP engagement during relapse, and the highest percentage of patients with ≥ 5 relapses coincided with the lowest frequency of HCP engagement during relapse. Key relapse-related and MS-related topics were discussed more by patients who always/often engage their HCP during relapse. HCP follow-up after relapse was variable, with 35.0% of patients reporting follow-up within 1 month of first contact, 50.3% reporting follow-up at the next office visit, and 14.7% reporting no follow-up. CONCLUSION: MS relapse remains particularly challenging for certain patients; some experience > 2 relapses in 1 year, relapse durations > 1 month, and relapse symptoms that interfere with daily functioning (e.g. walking/balance by 68.8%). Approximately 25% of patients reported rarely or never engaging their HCP during relapse. Common reasons for not engaging, like HCP helpfulness and treatment effectiveness/tolerance, warrant further exploration. Results indicating the benefits of timely touchpoints on both the part of the patient and HCP during relapse include the relationship between higher frequency of engagement with lower relapse frequency and more discussion of both relapse-related and MS-related discussion topics. Survey limitations apply.
BACKGROUND: Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). OBJECTIVE: To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Sclerosis in America (MSIA) 2017 survey. METHODS: Information on patient demographics, health insurance coverage, symptoms, disability, relapses, and related HCP interactions were captured. Descriptive analyses were conducted and relapses were annualized. Chi-square tests were used to evaluate frequency of patient engagement, i.e. speaking with or seeing their HCP during relapse with annualized relapse frequency and topics discussed. RESULTS: Of the 5,311 patient-respondents, the mean age was 51.2 years (84.3% female, 89.3% Caucasian); 40.1% were on disability, and 96.8% had health insurance coverage. A total of 72.2% of patients were diagnosed with relapsing-remitting MS (RRMS); 74.8% of patients not reporting a diagnosis of primary progressive MS (PPMS) (n = 4819) were using disease-modifying therapy. In the 2 years preceding the survey, 73.1% experienced a relapse for a median number of 2 relapses; this corresponded to an annualized relapse distribution among all patients of 44.1% with < 1 relapse, 35.5% with 1-2 relapses, and 20.2% with > 2 relapses. In patients reporting relapses, 62.5% cited an average relapse duration of < 1 month, 10.9% cited 1-2 months, and 13.6% cited > 2 months (12.9% were unsure/didn't recall). Leading symptoms experienced with MS relapse were fatigue (77.4%), numbness/tingling (70.0%), and walking or balance issues (68.8%). With respect to HCP engagement during relapse, 46.9% of patients reported doing so always/often, vs. sometimes (27.3%), rarely (18.5%), and never (7.3%). The most common reasons cited for not engaging an HCP were that the relapse was not severe enough (57.9%), the HCP was unhelpful or didn't specifically tell the patient to contact them (30.9%), the treatment didn't work well or wasn't tolerated (25.6%), or the preference to manage alone (24.4%). A higher percentage of patients with 1 relapse coincided with the highest frequency of HCP engagement during relapse, and the highest percentage of patients with ≥ 5 relapses coincided with the lowest frequency of HCP engagement during relapse. Key relapse-related and MS-related topics were discussed more by patients who always/often engage their HCP during relapse. HCP follow-up after relapse was variable, with 35.0% of patients reporting follow-up within 1 month of first contact, 50.3% reporting follow-up at the next office visit, and 14.7% reporting no follow-up. CONCLUSION: MS relapse remains particularly challenging for certain patients; some experience > 2 relapses in 1 year, relapse durations > 1 month, and relapse symptoms that interfere with daily functioning (e.g. walking/balance by 68.8%). Approximately 25% of patients reported rarely or never engaging their HCP during relapse. Common reasons for not engaging, like HCP helpfulness and treatment effectiveness/tolerance, warrant further exploration. Results indicating the benefits of timely touchpoints on both the part of the patient and HCP during relapse include the relationship between higher frequency of engagement with lower relapse frequency and more discussion of both relapse-related and MS-related discussion topics. Survey limitations apply.
Authors: Samuel F Hunter; Jas Bindra; Ishveen Chopra; John Niewoehner; Mary P Panaccio; George J Wan Journal: Clinicoecon Outcomes Res Date: 2021-10-11
Authors: Jeri Burtchell; Daisy Clemmons; Joann Clemmons; Tim Sabutis; Adeline Rosenberg; Jennifer Graves; Michael L Sweeney; John Kramer; Marina Ziehn; Brandon Brown; Jamie L Weiss; Ahmed Z Obeidat Journal: Neurol Ther Date: 2022-05-24
Authors: Ellen M Mowry; Robert A Bermel; James R Williams; Tammie L S Benzinger; Carl de Moor; Elizabeth Fisher; Carrie M Hersh; Megan H Hyland; Izlem Izbudak; Stephen E Jones; Bernd C Kieseier; Hagen H Kitzler; Lauren Krupp; Yvonne W Lui; Xavier Montalban; Robert T Naismith; Jacqueline A Nicholas; Fabio Pellegrini; Alex Rovira; Maximilian Schulze; Björn Tackenberg; Mar Tintore; Madalina E Tivarus; Tjalf Ziemssen; Richard A Rudick Journal: Front Neurol Date: 2020-08-07 Impact factor: 4.003
Authors: J Bradford Rice; Mary P Panaccio; Alan White; Mark Simes; Emma Billmyer; Nathaniel Downes; John Niewoehner; George J Wan Journal: Neurol Ther Date: 2020-11-10